Skip to main content
Erschienen in: Clinical Orthopaedics and Related Research® 9/2008

01.09.2008 | Symposium: Molecular Genetics in Sarcoma

Global Protein-expression Analysis of Bone and Soft Tissue Sarcomas

verfasst von: Akira Kawai, MD, PhD, Tadashi Kondo, MD, PhD, Yoshiyuki Suehara, MD, PhD, Kazutaka Kikuta, MD, Setsuo Hirohashi, MD, PhD

Erschienen in: Clinical Orthopaedics and Related Research® | Ausgabe 9/2008

Einloggen, um Zugang zu erhalten

Abstract

Analysis of global protein expression, an approach known as expression proteomics, can offer important clues for understanding tumor biology that cannot be obtained by other approaches (e.g., genome or transcriptome analysis). Using two-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry, we performed global protein expression studies of bone and soft tissue sarcomas to develop novel diagnostic and therapeutic biomarkers and allow molecular classification of the tumors. Among 1500 protein variants identified in the two-dimensional gel, 67 proteins correctly distinguished the eight subtypes of 99 histologically classified soft tissue sarcomas. Hierarchical clustering demonstrated leiomyosarcoma and MFH shared a similar protein expression profile, and clear cell sarcoma, synovial sarcoma, and MPNST could be grouped according to their protein expression patterns. Pleomorphic leiomyosarcoma and MFH showed similar tropomyosin isoform expression patterns. Patients with gastrointestinal stromal tumors expressing pfetin protein had better survival than those whose tumors lacked it. We identified 10 protein spots associated with the chemosensitivity of osteosarcoma to preoperative chemotherapy. These 10 spots could be new diagnostic and prognostic markers for osteosarcoma and new therapeutic targets for the disease. Proteomic analysis using 2D-DIGE provides novel information on the biology of bone and soft tissue sarcomas that could be used to diagnosis and treat these tumors.
Level of Evidence: Level II, diagnostic study. See the Guidelines for Authors for a complete description of levels of evidence.
Literatur
1.
Zurück zum Zitat Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, Bacchini P, Brach del Prever A, Tienghi A, Camandone A, Campanacci M. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998;16:658-663.PubMed Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, Bacchini P, Brach del Prever A, Tienghi A, Camandone A, Campanacci M. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998;16:658-663.PubMed
2.
Zurück zum Zitat Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer. 2005;41:2836–2845.PubMedCrossRef Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer. 2005;41:2836–2845.PubMedCrossRef
3.
Zurück zum Zitat Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M, Serra M. Expression of p-glycoprotein in high-grade osteosarcoma in relation to clinical outcome. N Engl J Med. 1995;333:1380–1385.PubMedCrossRef Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M, Serra M. Expression of p-glycoprotein in high-grade osteosarcoma in relation to clinical outcome. N Engl J Med. 1995;333:1380–1385.PubMedCrossRef
4.
Zurück zum Zitat Chen G, Gharib TG, Huang CC, Taylor JMG, Misek DE, Kardia SLR, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002;1:304–313.PubMedCrossRef Chen G, Gharib TG, Huang CC, Taylor JMG, Misek DE, Kardia SLR, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002;1:304–313.PubMedCrossRef
7.
Zurück zum Zitat Fletcher CDM, Gustafson P, Rydholm A, Willen H, Akerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol. 2001;19:3045–3050.PubMed Fletcher CDM, Gustafson P, Rydholm A, Willen H, Akerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol. 2001;19:3045–3050.PubMed
8.
Zurück zum Zitat Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JVS, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13:1367–1373.PubMedCrossRef Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JVS, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13:1367–1373.PubMedCrossRef
9.
Zurück zum Zitat Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Miser JS. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694–701.PubMedCrossRef Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Miser JS. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694–701.PubMedCrossRef
10.
11.
Zurück zum Zitat Guillou L, Coindre JM, Bonichon F, Bui NB, Terrier P, Collin F, Vilain MO, Mandard AM, Doussal VL, Leroux A, Jacquemier J, Duplay H, Sastre-Garau X, Costa J. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15:350–362.PubMed Guillou L, Coindre JM, Bonichon F, Bui NB, Terrier P, Collin F, Vilain MO, Mandard AM, Doussal VL, Leroux A, Jacquemier J, Duplay H, Sastre-Garau X, Costa J. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15:350–362.PubMed
12.
Zurück zum Zitat Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol. 1999;19:1720–1730.PubMed Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol. 1999;19:1720–1730.PubMed
13.
Zurück zum Zitat Hasegawa T, Hasegawa F, Hirose T, Sano T, Matsuno Y. Expression of smooth muscle markers in so called malignant fibrous histiocytomas. J Clin Pathol. 2003;56:666–671.PubMedCrossRef Hasegawa T, Hasegawa F, Hirose T, Sano T, Matsuno Y. Expression of smooth muscle markers in so called malignant fibrous histiocytomas. J Clin Pathol. 2003;56:666–671.PubMedCrossRef
14.
Zurück zum Zitat Holt GE, Schwartz HS, Caldwell RL. Proteomic profiling in musculoskeletal oncology by MALDI mass spectrometry. Clin Orthop Relat Res. 2006;450:105–110.PubMedCrossRef Holt GE, Schwartz HS, Caldwell RL. Proteomic profiling in musculoskeletal oncology by MALDI mass spectrometry. Clin Orthop Relat Res. 2006;450:105–110.PubMedCrossRef
15.
Zurück zum Zitat Ifergan I, Meller I, Issakov J, Assaraf YG. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer. 2003;98:1958–1966.PubMedCrossRef Ifergan I, Meller I, Issakov J, Assaraf YG. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer. 2003;98:1958–1966.PubMedCrossRef
16.
17.
Zurück zum Zitat Kakar S, Mihalov M, Chachlani NA, Ghosh L, Johnstone H. Correlation of c-fos, p53, and PCNA expression with treatment outcome in osteosarcoma. J Surg Oncol. 2000;73:125–126.PubMedCrossRef Kakar S, Mihalov M, Chachlani NA, Ghosh L, Johnstone H. Correlation of c-fos, p53, and PCNA expression with treatment outcome in osteosarcoma. J Surg Oncol. 2000;73:125–126.PubMedCrossRef
18.
Zurück zum Zitat Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, Ho AD, Egerer G. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant. 2004;34:37–41.PubMedCrossRef Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, Ho AD, Egerer G. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant. 2004;34:37–41.PubMedCrossRef
19.
Zurück zum Zitat Kawai A, Hosono A, Nakayama R, Matsumine A, Matsumoto S, Ueda T, Tsuchiya H, Beppu Y, Morioka H, Yabe H. Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients. Cancer. 2007;109:109–116.PubMedCrossRef Kawai A, Hosono A, Nakayama R, Matsumine A, Matsumoto S, Ueda T, Tsuchiya H, Beppu Y, Morioka H, Yabe H. Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients. Cancer. 2007;109:109–116.PubMedCrossRef
20.
Zurück zum Zitat Kawai A, Muschler GF, Lane JM, Otis JC, Healey JH. Prosthetic knee replacement after resection of a malignant tumor of the distal part of the femur. J Bone Joint Surg Am. 1998;80:636–647.PubMedCrossRef Kawai A, Muschler GF, Lane JM, Otis JC, Healey JH. Prosthetic knee replacement after resection of a malignant tumor of the distal part of the femur. J Bone Joint Surg Am. 1998;80:636–647.PubMedCrossRef
21.
Zurück zum Zitat Kondo T, Hirohashi S. Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc. 2007;1:2940–2956.CrossRef Kondo T, Hirohashi S. Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc. 2007;1:2940–2956.CrossRef
22.
Zurück zum Zitat Kondo T, Seike M, Mori Y, Fujii K, Yamada T, Hirohashi S. Application of sensitive fluorescent dyes in linkage of laser microdissection and two-dimensional gel electrophoresis as a cancer proteomic study tool. Proteomics. 2003;3:1758–1766.PubMedCrossRef Kondo T, Seike M, Mori Y, Fujii K, Yamada T, Hirohashi S. Application of sensitive fluorescent dyes in linkage of laser microdissection and two-dimensional gel electrophoresis as a cancer proteomic study tool. Proteomics. 2003;3:1758–1766.PubMedCrossRef
23.
Zurück zum Zitat Kusuzaki K, Takeshita H, Murata H, Hirata M, Hashiguchi S, Ashihara T, Hirasawa Y. Relation between cellular doxorubicin binding ability to nuclear DNA and histologic response to preoperative chemotherapy in patients with osteosarcoma. Cancer. 1998;82:2343–2349.PubMedCrossRef Kusuzaki K, Takeshita H, Murata H, Hirata M, Hashiguchi S, Ashihara T, Hirasawa Y. Relation between cellular doxorubicin binding ability to nuclear DNA and histologic response to preoperative chemotherapy in patients with osteosarcoma. Cancer. 1998;82:2343–2349.PubMedCrossRef
24.
Zurück zum Zitat Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene. 2001;5755–5762. Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene. 2001;5755–5762.
25.
Zurück zum Zitat Lee YF, John M, Edwards S, Clark J, Flohr P, Maillard K, Edema M, Baker L, Mangham DC, Grimer R, Wooster R, Thomas JM, Fisher C, Judson I, Cooper CS. Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer. 2003;88:510–515.PubMedCrossRef Lee YF, John M, Edwards S, Clark J, Flohr P, Maillard K, Edema M, Baker L, Mangham DC, Grimer R, Wooster R, Thomas JM, Fisher C, Judson I, Cooper CS. Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer. 2003;88:510–515.PubMedCrossRef
26.
Zurück zum Zitat Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, Casali PG, Gronchi A. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer. 2005;103:402–408.PubMedCrossRef Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, Casali PG, Gronchi A. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer. 2005;103:402–408.PubMedCrossRef
27.
Zurück zum Zitat Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. The Oncologist. 2004;9:422–441.PubMedCrossRef Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. The Oncologist. 2004;9:422–441.PubMedCrossRef
28.
Zurück zum Zitat Milano A, Apice G, Ferrari E, Fazioli F, de Rosa V, de Luna AS, Iaffaioli RV, Caponigro F. New emerging drugs in soft tissue sarcoma. Crit Rev Oncol Hematol. 2006;59:74–84.PubMedCrossRef Milano A, Apice G, Ferrari E, Fazioli F, de Rosa V, de Luna AS, Iaffaioli RV, Caponigro F. New emerging drugs in soft tissue sarcoma. Crit Rev Oncol Hematol. 2006;59:74–84.PubMedCrossRef
29.
Zurück zum Zitat Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, LaFleur B, McDonough WS, Henry MM, Ramsey KE, Antonescu CR, Chen W, Healey JH, Daluski A, Berens ME, MacDonald TJ, Gorlick R, Stephan DA. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005;65:1748–1754.PubMedCrossRef Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, LaFleur B, McDonough WS, Henry MM, Ramsey KE, Antonescu CR, Chen W, Healey JH, Daluski A, Berens ME, MacDonald TJ, Gorlick R, Stephan DA. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005;65:1748–1754.PubMedCrossRef
30.
Zurück zum Zitat Nagayama S, Katagiri T, Tsunoda T, Hosaka T, Nakashima Y, Araki N, Kusuzaki K, Nakayama T, Tsuboyama T, Nakamura T, Imamura M, Nakamura Y, Toguchida J. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res. 2002;62:5859–5866.PubMed Nagayama S, Katagiri T, Tsunoda T, Hosaka T, Nakashima Y, Araki N, Kusuzaki K, Nakayama T, Tsuboyama T, Nakamura T, Imamura M, Nakamura Y, Toguchida J. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res. 2002;62:5859–5866.PubMed
31.
Zurück zum Zitat Nakayama R, Nemoto T, Takahashi H, Ohta T, Kawai A, Seki K, Yoshida T, Toyama Y, Ichikawa H, Hasegawa T. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol. 2007;20:749–759.PubMedCrossRef Nakayama R, Nemoto T, Takahashi H, Ohta T, Kawai A, Seki K, Yoshida T, Toyama Y, Ichikawa H, Hasegawa T. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol. 2007;20:749–759.PubMedCrossRef
32.
Zurück zum Zitat Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O’Connell JX, Zhu S, Fero M, Sherlock G, Pollack JR, Brown PO, Botstein D, van de Rijn M. Molecular characterization of soft tissue tumours: a gene expression study. Lancet. 2002;359:1301–1307.PubMedCrossRef Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O’Connell JX, Zhu S, Fero M, Sherlock G, Pollack JR, Brown PO, Botstein D, van de Rijn M. Molecular characterization of soft tissue tumours: a gene expression study. Lancet. 2002;359:1301–1307.PubMedCrossRef
33.
Zurück zum Zitat Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C, Plouvier E, Lejars O, Rubie H, Terrier P, Michon J. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors. J Clin Oncol. 2006;24:3997–4002.PubMedCrossRef Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C, Plouvier E, Lejars O, Rubie H, Terrier P, Michon J. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors. J Clin Oncol. 2006;24:3997–4002.PubMedCrossRef
34.
Zurück zum Zitat Ochi K, Daigo Y, Katagiri T, Nagayama S, Tsunoda T, Myoui A, Naka N, Araki N, Kudawara I, Ieguchi M, Toyama Y, Toguchida J, Yoshikawa H, Nakamura Y. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol. 2004;24:647–655.PubMed Ochi K, Daigo Y, Katagiri T, Nagayama S, Tsunoda T, Myoui A, Naka N, Araki N, Kudawara I, Ieguchi M, Toyama Y, Toguchida J, Yoshikawa H, Nakamura Y. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol. 2004;24:647–655.PubMed
35.
Zurück zum Zitat Resendes BL, Kuo SF, Robertson NG, Giersch ABS, Honrubia D, Ohara O, Adams JC, Morton CC. Isolation from cochlea of a novel human intronless gene with predominant fetal expression. J Assoc Res Otolaryngol. 2004;5:185–202.PubMed Resendes BL, Kuo SF, Robertson NG, Giersch ABS, Honrubia D, Ohara O, Adams JC, Morton CC. Isolation from cochlea of a novel human intronless gene with predominant fetal expression. J Assoc Res Otolaryngol. 2004;5:185–202.PubMed
36.
Zurück zum Zitat Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;15:1221–1230.CrossRef Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;15:1221–1230.CrossRef
37.
Zurück zum Zitat Suehara Y, Kondo T, Fujii K, Hasegawa T, Kawai A, Seki K, Beppu Y, Nishimura T, Kurosawa H, Hirohashi S. Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas. Proteomics. 2006;6:4402–4409.PubMedCrossRef Suehara Y, Kondo T, Fujii K, Hasegawa T, Kawai A, Seki K, Beppu Y, Nishimura T, Kurosawa H, Hirohashi S. Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas. Proteomics. 2006;6:4402–4409.PubMedCrossRef
38.
Zurück zum Zitat Suehara Y, Kondo T, Seki K, Shibata T, Fujii K, Goto M, Hasegawa T, Shimada Y, Sasako M, Shimoda T, Kurosawa H, Beppu Y, Kawai A, Hirohashi S. Pfetin, as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res. 2008;14:1707–1717.PubMedCrossRef Suehara Y, Kondo T, Seki K, Shibata T, Fujii K, Goto M, Hasegawa T, Shimada Y, Sasako M, Shimoda T, Kurosawa H, Beppu Y, Kawai A, Hirohashi S. Pfetin, as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res. 2008;14:1707–1717.PubMedCrossRef
39.
Zurück zum Zitat Tschoep K, Kohlmann A, Schlemmer M, Haferlach T, Issels RD. Gene expression profiling in sarcomas. Crit Rev Oncol Hematol. 2007;63:111–124.PubMedCrossRef Tschoep K, Kohlmann A, Schlemmer M, Haferlach T, Issels RD. Gene expression profiling in sarcomas. Crit Rev Oncol Hematol. 2007;63:111–124.PubMedCrossRef
40.
Zurück zum Zitat Tunn PU, Schmidt-Peter P, Pomraenke D, Hohenberger P. Osteosarcoma in children: long-term functional analysis. Clin Orthop Relat Res. 2004;421:212–217.PubMedCrossRef Tunn PU, Schmidt-Peter P, Pomraenke D, Hohenberger P. Osteosarcoma in children: long-term functional analysis. Clin Orthop Relat Res. 2004;421:212–217.PubMedCrossRef
41.
Zurück zum Zitat Van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer. 2005;104:1781–1788.PubMedCrossRef Van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer. 2005;104:1781–1788.PubMedCrossRef
Metadaten
Titel
Global Protein-expression Analysis of Bone and Soft Tissue Sarcomas
verfasst von
Akira Kawai, MD, PhD
Tadashi Kondo, MD, PhD
Yoshiyuki Suehara, MD, PhD
Kazutaka Kikuta, MD
Setsuo Hirohashi, MD, PhD
Publikationsdatum
01.09.2008
Verlag
Springer-Verlag
Erschienen in
Clinical Orthopaedics and Related Research® / Ausgabe 9/2008
Print ISSN: 0009-921X
Elektronische ISSN: 1528-1132
DOI
https://doi.org/10.1007/s11999-008-0330-4

Weitere Artikel der Ausgabe 9/2008

Clinical Orthopaedics and Related Research® 9/2008 Zur Ausgabe

Symposium: Molecular Genetics in Sarcoma

Hypoxia Markers in Human Osteosarcoma: An Exploratory Study

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.